Paclitaxel-carboplatin chemotherapy does not cause encephalopathy in patients with ovarian cancer: A prospective EEG mapping study in 28 patients

Anticancer Research

Volumn 21, Issue 1 B, 2001, Pages 803-808

  Mayerhofer, K ^a   Bodner, K ^a   Saletu, B ^a   Bodner Adler, B ^a   Anderer, P ^a   Hefler, L ^a   Schindl, M ^a   Kaider, A ^a   Leodolter, S ^a   Kainz, C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

EEG mapping; Encephalopathy; Ovarian cancer paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER GRADING; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; DISEASE CLASSIFICATION; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; TREATMENT PLANNING;

ADENOCARCINOMA; ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN DISEASES; BRAIN MAPPING; CARBOPLATIN; CARCINOMA, ENDOMETRIOID; COGNITION DISORDERS; DEXAMETHASONE; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES;

EID: 0035056403     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Cancer statistics
2. The combination of paclitaxel and carboplatin as first-line chemotherapy in patients with stage III and stage IV ovarian cancer: A phase I-II study
3. Taxol in ovarian cancer
4. Promotion of microtubule assembly in vitro by taxol
5. Taxol as a second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy
6. Peripheral neurotoxicity of Taxol in patients previously treated with Cisplatin
7. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat
8. Transient encephalopathy after paclitaxel (Taxol) infusion
9. Ariffact processing in topographic mapping of Electroencephalographic activity in neuropsychopharmacology
10. Restriction to a limited set of EEG-target variables may lead to misinterpretation of pharmaco-EEG results
11. Hormonal, syndromal and EEG mapping studies in menopausal syndrome patients with and without depression as compared with controls
12. Reporting results of cancer treatment
13. Topographic brain mapping of EEH in neuropsychopharmacology- part I. Methodological aspects
14. The conception of nervous and mental energy. II. Vigilance: A physiological state of the nervous system
15. Monitoring for target objects: Activation of right frontal and parietal cortices with increasing time on task
16. Metabolic brain pattern of sustained auditory discrimination
17. Differential effects of normal aging on sources of standard N1, target N1 and target P 300 auditory event- related brain potentials revealed by low resolution electromagnetic tomography (LORETA)
18. Quality of life during chemotherapy for small cell lung cancer
19. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms
20. A phase 1 trial of taxol given by a 6- hour intravenous infusion
21. Phase I study of paclitaxel in patients with recurrent malignant glioma: A north american brain tumor consortium report
22. Acute encephalopathy: A new toxicity associated with high-dose paclitaxel